L. Isa

753 total citations
18 papers, 484 citations indexed

About

L. Isa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, L. Isa has authored 18 papers receiving a total of 484 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 2 papers in Surgery. Recurrent topics in L. Isa's work include Cancer Treatment and Pharmacology (7 papers), Lung Cancer Treatments and Mutations (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). L. Isa is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Lung Cancer Treatments and Mutations (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). L. Isa collaborates with scholars based in Italy, United States and Malaysia. L. Isa's co-authors include L Brancaccio, Francesco Perrone, Ciro Gallo, Cesare Gridelli, Santi Barbera, Massimo Di Maïo, L. Frontini, Alberto Zaniboni, Irene Floriani and Sandro Barni and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

L. Isa

18 papers receiving 465 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L. Isa Italy 8 349 243 68 64 55 18 484
Francovito Piantedosi Italy 7 507 1.5× 472 1.9× 18 0.3× 70 1.1× 14 0.3× 12 774
Laura Prakash United States 17 615 1.8× 259 1.1× 37 0.5× 322 5.0× 27 0.5× 39 733
Marybeth Singer United States 8 435 1.2× 51 0.2× 19 0.3× 234 3.7× 11 0.2× 12 518
Beth Eaby United States 8 424 1.2× 180 0.7× 11 0.2× 189 3.0× 8 0.1× 10 665
Francesco Carrozza Italy 10 183 0.5× 230 0.9× 63 0.9× 58 0.9× 2 0.0× 26 384
Aamer Mahmud Canada 9 146 0.4× 110 0.5× 21 0.3× 235 3.7× 7 0.1× 21 355
Yutian Lai China 14 264 0.8× 424 1.7× 26 0.4× 259 4.0× 4 0.1× 55 761
Katerina Zakka United States 12 191 0.5× 58 0.2× 6 0.1× 87 1.4× 27 0.5× 36 372
Carmine La Manna Italy 14 192 0.6× 415 1.7× 58 0.9× 199 3.1× 9 0.2× 26 639
Anneli Elme Estonia 11 374 1.1× 230 0.9× 3 0.0× 128 2.0× 12 0.2× 23 524

Countries citing papers authored by L. Isa

Since Specialization
Citations

This map shows the geographic impact of L. Isa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Isa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Isa more than expected).

Fields of papers citing papers by L. Isa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Isa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Isa. The network helps show where L. Isa may publish in the future.

Co-authorship network of co-authors of L. Isa

This figure shows the co-authorship network connecting the top 25 collaborators of L. Isa. A scholar is included among the top collaborators of L. Isa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Isa. L. Isa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Teh, Cheng Lay, et al.. (2024). Economic burden of systemic lupus erythematosus in Malaysia. Journal of Medical Economics. 27(sup1). 46–55. 1 indexed citations
2.
3.
Buzzoni, Roberto, Sara Pusceddu, Pamela Biondani, et al.. (2011). 6626 POSTER Efficacy and Safety of RAD001 as Second Line Therapy in Biliary Tract Cancer (BTC) Patients (pts) – a Phase II I.T.M.O. (Italian Trials in Medical Oncology) Group Study. European Journal of Cancer. 47. S479–S480. 1 indexed citations
4.
Labianca, Roberto, Alberto F. Sobrero, L. Isa, et al.. (2010). Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trial. Annals of Oncology. 22(5). 1236–1242. 72 indexed citations
5.
6.
Magagnoli, Massimo, Michele Spina, Monica Balzarotti, et al.. (2007). IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplantation. 40(11). 1019–1025. 15 indexed citations
7.
Bajetta, Emilio, Maria Di Bartolomeo, Roberto Buzzoni, et al.. (2007). Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. British Journal of Cancer. 96(3). 439–444. 32 indexed citations
8.
Bidoli, Paolo, Nicoletta Zilembo, Diego Cortinovis, et al.. (2006). Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. Annals of Oncology. 18(3). 461–467. 28 indexed citations
9.
Fagnani, Daniele, Riccardo Franchi, Camillo Porta, et al.. (2006). Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis. Annals of Oncology. 18(3). 551–555. 23 indexed citations
10.
Maio, Marco Di, Ciro Gallo, A. Ceribelli, et al.. (2006). Two-drug gemcitabine-based first-line treatment of elderly patients (pts) with small cell lung cancer (SCLC): The G-STEP program. Journal of Clinical Oncology. 24(18_suppl). 7089–7089. 2 indexed citations
11.
Labianca, Roberto, Irene Floriani, Enrico Cortesi, et al.. (2006). Alternating versus continuous “FOLFIRI” in advanced colorectal cancer (ACC): A randomized “GISCAD” trial. Journal of Clinical Oncology. 24(18_suppl). 3505–3505. 44 indexed citations
12.
Frontini, L., A Ardizzoia, M. Giordano, et al.. (2005). Epirubicine-vinorelbine (EV) intravenous combination followed by oral vinorelbine (VNR) as first-line treatment in advanced breast cancer (ABC) patients: A POLONORD Group study. Journal of Clinical Oncology. 23(16_suppl). 770–770. 5 indexed citations
13.
14.
Gridelli, Cesare, Ciro Gallo, Massimo Di Maïo, et al.. (2004). A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. British Journal of Cancer. 91(12). 1996–2004. 143 indexed citations
15.
Maïo, Massimo Di, Cesare Gridelli, Ciro Gallo, et al.. (2004). Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. British Journal of Cancer. 90(12). 2288–2296. 102 indexed citations
16.
Piazza, E., et al.. (1997). 138 Gemcitabine in the treatment of pretreated metastatic non small cell lung cancer: A preliminary report. Lung Cancer. 18. 38–38. 2 indexed citations
17.
Piazza, E., V. Filipazzi, L. Isa, et al.. (1994). Cisplatin-vinorelbine (DDP+VBN) association chemotherapy in the treatment of locally advanced N.S.C.L.C.. Lung Cancer. 11. 128–128. 2 indexed citations
18.
Isa, L. & Stefano Lodi. (1985). RECURRENT INTRA‐UTERINE DEATHS, VENOUS THROMBOSIS AND “LUPUS ANTICOAGULANT”. Acta Obstetricia Et Gynecologica Scandinavica. 64(8). 689–690. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francovito Piantedosi Breakdown of academic impact, for papers by Laura Prakash Breakdown of academic impact, for papers by Marybeth Singer Breakdown of academic impact, for papers by Beth Eaby Breakdown of academic impact, for papers by Francesco Carrozza Breakdown of academic impact, for papers by Aamer Mahmud Breakdown of academic impact, for papers by Yutian Lai Breakdown of academic impact, for papers by Katerina Zakka Breakdown of academic impact, for papers by Carmine La Manna Breakdown of academic impact, for papers by Anneli Elme
Rankless by CCL
2026